Objective: Sudden arrhythmia death syndrome (SADS) accounts for about 30% of causes of sudden cardiac death (SCD) in young people. In Hong Kong, there are scarce data on SADS and a lack of experience in molecular autopsy. We aimed to investigate the value of molecular autopsy techniques for detecting SADS in an East Asian population.
Introduction
Sudden death is defined as death occurring within 1 hour of the onset of symptoms or within 24 hours of the victim being seen alive. 1 Sudden death due to an underlying heart disease is known as sudden cardiac death (SCD). The worldwide annual incidence of SCD is about 4 to 5 million cases per year. 2 A tragic and devastating complication of a number of heart diseases, SCD is most often unexpected and has major implications for the surviving family and the community. The majority of SCD cases in middleaged and older individuals are caused by coronary artery disease; however, SCD is rare in young people and the causes are more diversified. 3, 4 Autopsy studies have shown no structural heart disease was found in up to 30% of young SCD victims. [5] [6] [7] [8] Molecular autopsy was first described by Ackerman et al 9 in 1999, to determine the cause of death in uncertain cases after conventional autopsy by genetic analysis. Post-mortem genetic studies have shown that SCD in these victims can be caused by fatal arrhythmias secondary to a group of inheritable cardiac electrical disorders collectively known as sudden arrhythmia death syndrome (SADS). [10] [11] [12] [13] [14] These include Brugada syndrome (BrS), long QT syndrome (LQTS), short QT syndrome, catecholaminergic polymorphic ventricular tachycardia (CPVT), arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy (HCM), and other cardiomyopathies.
Because SADS-related conditions are genetic diseases, there are two different approaches to identify SADS among young sudden unexplained death (SUD) victims. The first approach involves detailed clinical and targeted genetic examination of the surviving relatives of SCD victims. Studies using this approach suggest that SADS may account for approximately 40% of autopsy-negative sudden death in young people. 10, 15 However, this approach may not be able to identify subjects with concealed form of SADS due to incomplete penetrance and variable expressivity of the pathological mutations. The second approach is to perform molecular autopsy on SCD victims, which involves post-mortem genetic testing for SADS. A landmark study on molecular autopsy by the Mayo Clinic showed over one third of SCD cases hosted a presumably pathogenic mutations of cardiac ion channel diseases. 8, 16 Thus a combined approach using both cardiac evaluation of surviving relatives and molecular autopsy on SUD victims should give a higher yield on elucidating the underlying causes of SUD.
In Hong Kong, there are scarce data on the prevalence and types of SADS underlying SCD or SUD in young people. The present study aimed to investigate the prevalence and types of SADS in an East Asian population, and to perform a pilot study on incorporating cardiac evaluation of surviving relatives and molecular autopsy by next-generation sequencing (NGS) into conventional forensic investigations.
Methods
In the present study, first, we carried out a 5-year retrospective review of the records of all autopsies for young sudden death victims performed in public mortuaries in Hong Kong. Second, we conducted a 2-year study to determine the prevalence and types of SADS as the underlying causes of SCD among local young victims through conventional and molecular autopsy, and evaluated their first-degree relatives.
Five-year retrospective review of autopsy records
The Forensic Pathology Service, Department of Health, provides all public autopsy services for over 7 million people in Hong Kong. We performed this retrospective review of the records of all autopsies in public mortuaries for young sudden death victims (aged 5-40 years) between 1 January 2008 and 31 December 2012. Sudden death was defined as death occurring within 1 hour of the onset of symptoms or within 24 hours of the victim being seen alive. 1 Sudden death victims were recruited into the study for a detailed review of their autopsy records. Data including age, height, weight, sex, circumstances of death, clinical history of cardiac disease, and pathologic findings at autopsy were collected and analysed. Sudden death victims whose deaths were caused by trauma, accidents, drowning, and drug toxicity, and those whose autopsy records were either incomplete or not accessible for retrospective review were excluded.
Two-year prospective study by conventional and molecular autopsy
In this prospective study, young SCD victims (aged 5-40 years) were identified and recruited into the study by forensic pathologists after a finding of either an inheritable arrhythmogenic cardiomyopathy or no anatomical cause of death (including other structural heart disease) on autopsy, and a negative toxicology screening. Clinical history, including personal history of arrhythmic events and history surrounding the sudden death event of the SCD victim was collected during identification interviews with next-of-kin as far as possible by forensic pathologists. DNAfriendly blood samples were collected for molecular autopsy. Written informed consent for a molecular autopsy was obtained from the next-of-kin of each victim. The first-degree relatives of the victims were referred by forensic pathologists to the study centre for genetic counselling and recruitment into the study. Clinical history, including personal history of arrhythmic events and history surrounding the sudden death event of the SCD victim was collected from family members. All recruited first-degree relatives underwent clinical evaluation including 12-lead electrocardiogram (ECG), signal-averaged ECG, echocardiogram, 24-hour Holter analysis and treadmill exercise testing. Additional investigations were used only as required, such as flecainide provocation testing (if BrS is suspected in subjects >18 years) and targeted genetic screening (if positive molecular autopsy findings in the index SUD victim). All first-degree relatives provided written informed consent for these procedures and for publication of the results.
A panel of 35 genes implicated in SADS for BrS, LQTS, short QT syndrome, CPVT, ARVC, and HCM was tested using NGS ( Table 1 ). The NGS was performed using targeted gene capture technique on a MiSeq Sequencing System (Illumina, Inc, San Diego [CA], United States). Target regions of interest were restricted to the coding regions and the 10-bp flanking regions. Target rates indicated percentage of bases with a minimum depth of coverage of 20×. Alignments to the February 2009 (GRCh37/ hg19) human genome assembly and variant calls were generated using dual pipelines, SoftGenetics NextGENe (v2.4.1) and an in-house one where sequencing reads were aligned by Burrows-Wheeler Aligner (v0.7.5a-r405) to hg19 genome and processed with picard-tools (v1.114). Local realignment for indels and base quality recalibration were performed 
Results

Five-year retrospective review of autopsy records
There were 17 187 autopsies performed during the study period and 2748 (16%) deaths were aged 5 to 40 years. There were 420 sudden death victims. Among them, 289 (69%) were SCD (male:female ratio=9:2). The median age was 32 years (range, 7-40 years). Coronary artery diseases accounted for 35% of the causes of death; other causes of death were aortic dissection (6%), myocarditis (6%), left ventricular hypertrophy (4%), dilated cardiomyopathy (9%), other structural heart diseases (9%), HCM (4%), ARVC (2%), and unexplained (25%).
Two-year study by conventional and molecular autopsy
There were 32 SCD victims aged 5 to 40 years between 1 July 2014 and 30 June 2016 with a finding of either an inheritable arrhythmogenic cardiomyopathy or no anatomical cause of death (including other structural heart disease) on autopsy and negative toxicology results. Eleven individuals were excluded: two who had no Hong Kong identity card and nine whose families refused consent. Finally, 21 SCD victims (18 male, 3 female) were recruited into the study. Table  2 shows the clinical and forensic data of the 21 SCD victims. The median age was 31 years (range, 14-39 years). From the conventional autopsy, 18 (86%) were unrevealing; two (10%) SCD victims had ARVC and one (5%) had HCM. The majority died during resting (48%) or sleeping (24%). Only three SCD victims (14%) died during exercise. Three (14%) SCD victims had family history of SCD and seven (33%) had a history of syncope. Many (71%) of the SCD victims had unremarkable past health. Genetic analysis showed 29% with positive heterozygous genetic variants (Table 3) . Seven variants were identified in seven genes, six variants of which were novel. The genetic background was heterogeneous without any common mutations found. Combining conventional and molecular autopsy findings, the cause of death in 12 (57%) still remains unknown; cause of death was confirmed in four (19%) as ARVC, in two (10%) as BrS, and one (5%) each in HCM, LQTS, and CPVT.
Overall, more than half of first-degree relatives (6 of 11 individuals) who underwent genetic testing carried the positive genetic variants. Among them, SADS-related clinical features were detected in three first-degree relatives from two families (cases 14 and 16). The true clinical phenotype can sometimes be detected in surviving relatives upon appropriate clinical evaluation, which in turn significantly aids the interpretation of genetic findings. Cases 14 and 16 illustrate the importance of this (Fig 1) . The firstdegree relatives of these two cases showed SADSrelated clinical features after cardiologist's assessment.
Case 14 was a 17-year-old male victim who died of sudden nocturnal death. He had an episode of syncope few months prior to his death but he did not seek medical attention. Family screening by clinical evaluation found no structural heart disease but ECG revealed prolonged QTc interval in his asymptomatic father and sister (530 ms and 480 ms, respectively) suggesting a diagnosis of LQTS (Fig 1) Case 16 was a 19-year-old male victim who also died of sudden nocturnal death. There was no known syncope or preceding symptoms ahead of the collapse. He had history of abnormal heart beat, although ECG was not done. His family history was unremarkable. Autopsy revealed pulmonary hypertension. Molecular autopsy detected heterozygous NM_198056.2(SCN5A):c.2893C>T (p.Arg965Cys) which has been reported as a disease causing mutation of BrS. [17] [18] [19] The same variant has also been reported in patients with LQTS (with digenic mutation in KCNH2 in one case). 20, 21 The allele frequency of this variant (rs199473180) is reported to be 0.058% in East Asians (gnomAD). In silico analyses by SIFT, MutationTaster, and PolyPhen-2 have revealed this variant to be damaging, disease causing, and probably damaging, respectively. Functional study showed that the p.(Arg965Cys) mutant led to slower recovery from inactivation as a result of channels with a more negative potential in steady state inactivation. 18 Family screening found his father carrying the same SCN5A mutation and a type 2 Brugada ECG pattern (Fig 1) . However, no type 1 Brugada ECG feature was revealed by a flecainide provocation test. The clinical phenotype in this case supports the pathogenicity of this novel genetic variant.
Discussion
To elucidate the cause of SCD, a comprehensive post-mortem evaluation is required. Figure 2 shows the combined approach using both cardiac evaluation of surviving relatives and molecular autopsy on SUD victims which would give a higher yield on elucidating the underlying causes of SUD. Any history of syncope, cardiac symptoms especially related to exertion, emotion and stress, previous ECG, circumstances of SCD (activity at the time of death), any family history of cardiac disease, premature or sudden death, near-arrest attack, and epilepsy should be investigated. Patients with SADS can present with or be (incorrectly) labelled as having epilepsy. [22] [23] [24] [25] Guidelines on post-mortem examination of SUD in the young have been published by the Royal College of Pathologists of Australasia (https://www.rcpa. edu.au/getattachment/89884c69-f066-411d-a3d1-39460444db13/Guidelines-on-Autopsy-Practice. aspx). In addition to traditional autopsy, some reports have used whole-body computed tomography and magnetic resonance imaging to identify structural heart abnormalities such as ARVC and HCM. 26, 27 However, these imaging modalities were not used in the present study.
Technologies applied in molecular autopsy have changed from Sanger sequencing targeting a 28 The former approach achieved diagnostic yields of around 15% to 20%. 8, 16, [29] [30] [31] [32] With increasing throughput capacities at more affordable costs, the large gene panel or exome approach by NGS is becoming more appealing in molecular autopsy. A proof-of-principle exomewide study was carried out among 50 SUD subjects, with likely pathogenic variants identified in 32%. 33 The diagnostic yield from various NGS studies, including our own, is up to 35%, despite the different lengths of gene lists. 13, [34] [35] [36] However, the spectrum of diseases might be different and rarer causes might be identified, because substantial clinical suspicion is typically lacking among young SCD victims with unremarkable premorbid history. However, a negative genetic result does not necessarily exclude the possibility of a genetic basis for the disease.
The major difficulty of molecular autopsy is establishing the causation between the death and the genetic variants. Applying molecular autopsy to the investigation of death causes involves probabilistic rather than binary "yes or no" answers. Interpretation of variant pathogenicity relies heavily on the characteristics of the genetic variant, allele rarity in population frequencies, in silico predictions, co-segregation patterns among affected family members, previous literature data on reports of similar cases, and available functional data. This approach follows the usual practice by which pathologists deal with genetic reporting.
There are two main advantages of molecular autopsy in SCD. First, molecular autopsy enables a correct diagnosis of SCD to be established, which can bring some level of closure to the family. Findings of a SADS-related condition can differentiate a natural cause from an unnatural cause of death, such as the possibility of drowning precipitated by an inherited arrhythmia during swimming. Second, the ultimate goal of diagnosing SCD is to prevent another tragedy among family members. The majority of SADSrelated disorders are autosomal dominant inherited, and family members are at 50% risk of inheriting the mutation, with variable penetrance. Family pedigree for at least three generations should be included in the extended clinical workup, and genetic counselling should be considered for second-or higher-degree relatives wherever appropriate.
There are limitations to our study. First, SCD victims with autopsy conducted in a public hospital were not recruited in this study. Hence, the sample numbers may not be representative for the whole territory. Second, no premorbid ECG findings of the victims were available to correlate with the genetic results. Third, despite multiple efforts, no genetic mutations were found in over two thirds of the SCD victims in our study. Expanding the gene list may be able to increase the yield. The associated phenotypes 
Conclusion
Sudden arrhythmia death syndrome is a significant cause of SCD in the young. This study is first of its kind in an East Asian population and provides important data on the prevalence and types of SADS among young SCD victims. This is also the first local feasibility study on incorporating cardiac evaluation of surviving relatives and NGS molecular autopsy into the conventional forensic investigations. The interpretation of genetic variants in the context of SCD is complicated and we recommend its analysis and reporting by qualified pathologists. This model may be considered to cover all age-groups of SCD victims, as well as other potential applications such as sudden unexpected death in epilepsy, or sudden infant death syndrome. This local pilot study should be considered an important advance in diagnosing young SCD victims in East Asian populations.
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